2026-04-29T14:23:06-04:00 2025-12-31 221866743 GERMAN VREELAND & ASSOCIATES LLP 2 RIDGEDALE AVE STE 300 CEDAR KNOLLS NJ 07927 990 2025-01-01 133174839 THE GLAUCOMA FOUNDATION INC GLAU 2126511900 80 MAIDEN LANE SUITE 700 NEW YORK NY 10038 ELENA STURMAN PRESIDENT & CEO 2126511900 2026-04-27 true VICTOR MAISANO CPA P00359999 9736052777 2026-04-29 2025 2025-03-06 01:10:19Z ELENA STURMAN 80 MAIDEN LANE SUITE 700 700 NEW YORK NY 10038 7450156 false X GLAUCOMAFOUNDATION.ORG X 1984 NY THE GLAUCOMA FOUNDATION, INC. IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA. 22 22 5 60 0 4042875 5045092 0 487037 917900 0 4529912 5962992 1162562 982807 0 929663 977635 30875 17250 344659 949138 1080859 3072238 3058551 1457674 2904441 17585178 20750332 1402985 1458790 16182193 19291542 X THE GLAUCOMA FOUNDATION, INC. IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA, THE LEADING CAUSE OF PREVENTABLE BLINDNESS. THE STRATEGY TO ACHIEVE THIS GOAL IS TWO-FOLD: RAISE PUBLIC AWARENESS CONCERNING THE NECESSITY OF ROUTINE EYE EXAMS, AND FUND CRITICAL RESEARCH TO FIND CURES FOR GLAUCOMA. false false 865695 1) MULTIPLE WEBINARS: WHAT DO COLD HANDS HAVE TO DO WITH GLAUCOMA? THE PROMISE OF OPTIC NERVE REGENERATION; THE BODY-EYE RELATIONSHIP HOW TO SAVE THE SIGHT OF PATIENTS WITH GLAUCOMA WHILE MINIMIZING ADVERSE REACTION FROM EYE DROPS; INSIGHTS INTO GLAUCOMA & WOMEN'S HEALTH: EXPLORING THE IMPACT OF MENOPAUSE AND VISUAL FUNCTION; GLAUCOMA AND LIFESTYLE. 2) THE OPTIC NERVE RESCUE AND RESTORATION THINK TANK "A PATIENT-CENTRIC APPROACH WHILE INCORPORATING THE LATEST SCIENCE" GLAUCOMA DATA INTEGRATION: OVERVIEW OF DATABASES AVAILABLE TO ADVANCE GLAUCOMA KNOWLEDGE; LESSONS LEARNED ABOUT GLAUCOMA FROM THE UK BIOBANK; POAG GENOMIC ARCHITECTURE; A 360-DEGREE BIOMEDICAL PROFILE OF HEALTH: LESSONS FROM CARDIOVASCULAR DISEASE. 3) DRUG RE-PURPOSING IN GLAUCOMA: INSULIN SIGNALING AND; METFORMIN AND GLAUCOMA; GLP-1R AGONISTS AND GLAUCOMA. 4) OVERVIEW OF GLAUCOMA NEUROPROTECTION AGENTS: WHY DO WE NOT HAVE A NEUROPROTECTION AGENT FOR GLAUCOMA? HOW CAN AI HELP FACILITATE RANDOMIZED CLINICAL TRIALS IN NEUROPROTECTION? 5) SEX HORMONES AND GLAUCOMA: THE ROLE OF SEX HORMONES IN THE PATHOGENESIS OF OPEN-ANGLE GLAUCOMA: EVIDENCE FROM EPIDEMIOLOGICAL STUDIES; ESTROGEN SIGNALING PATHWAYS IN GLAUCOMA; THE BIOMECHANICAL ARGUMENT THAT ESTROGEN PLAYS A ROLE IN GLAUCOMA; 6) NON-IOP FACTORS OF IMPORTANCE IN GLAUCOMA: DIET AND GLAUCOMA; HYPERTENSION, ANTIHYPERTENSIVE DRUGS AND GLAUCOMA; THE IMPACT OF GLAUCOMA ON ACTIVITIES OF DAILY LIVING. 7) WHAT CAN TGF DO TO HELP PATIENTS, RESEARCHERS, AND EYECARE PROVIDERS TACKLE GLAUCOMA?: WHAT IS THE GLAUCOMA FOUNDATION DOING NOW? WHAT DO PATIENTS WANT TO SEE IN GLAUCOMA RESEARCH? 8) START WITH THE YOUNG: INFO SESSION ON GLAUCOMA FOR MIDDLE AND HIGH SCHOOL STUDENTS; IN COORDINATION WITH THE STEM INSTITUTE AT THE CITY COLLEGE OF NEW YORK. 9) NEWSLETTERS: TGF PRODUCED SIX ELECTRONIC NEWSLETTERS THAT WERE DISTRIBUTED TO MORE THAN 16,000 HOUSEHOLDS. TGF'S QUARTERLY PRINTED NEWSLETTERS WERE AVAILABLE FOR CONSTITUENTS WHO DO NOT USE COMPUTERS OR WHO PREFER TO READ PAPER DOCUMENTS. NEWSLETTERS INCLUDE INTERVIEWS WITH DOCTORS, RESEARCHERS, AND PATIENTS. THEY COVER TOPICS SUCH AS ADVANCEMENTS IN DIAGNOSIS AND TREATMENT, PERSPECTIVES ON CARE, AND PERSONAL STORIES OF LIVING WITH THE DISEASE. 1509236 982807 1) GENETIC PREDISPOSITION AND OPHTHALMIC OUTCOMES; 2) OPTIC NERVE REGENERATION; 3) USING ARTIFICIAL INTELLIGENCE TO REVEAL BLOOD PRESSURE'S ROLE IN GLAUCOMA PROGRESSION; 4) EE-PURPOSING AN "OLD" DRUG FOR A NEW INDICATION: ELUCIDATING THE PERIPHERAL AND CENTRAL EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS TO TREAT GLAUCOMA; 5) SEARCH FOR FUNCTIONAL LOXL1 RISK ALLELES WITH BIT-STARR; 6) VASCULAR GENOTYPE-PHENOTYPE ASSOCIATION IN PRIMARY OPEN-ANGLE GLAUCOMA; 7) INVESTIGATING THE ROLE OF IMPAIRED MITOCHONDRIAL DYNAMICS IN EXFOLIATION GLAUCOMA; 8) UNCOVERING THE POTENTIAL OF PERICYTES AS THERAPEUTIC TARGETS FOR GLAUCOMA; 9) NICOTINAMIDE AND PYRUVATE FOR NEUROENHANCEMENT IN OPEN-ANGLE GLAUCOMA: A PHASE 2 RANDOMIZED CLINICAL TRIAL. 2374931 true true false false false false false false false true true false false false true true true false false false true true false true true false false true false true false false false false false false false false true false false false false false false false false true 11 0 5 true false false false false false false false false false false false false false false X 22 22 false false false false false false false true true false false true true true true true true true true false NY AL AK AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X ELENA STURMAN 2126511900 80 MAIDEN LANE SUITE 700 NEW YORK NY 10038 ELENA STURMAN PRESIDENT & 40.00 X 421776 0 22557 ELENA CLY FOWKES DIR OF SPECI 40.00 X 143934 0 22557 ANDREA STEELE CHIEF OPERAT 40.00 X 120294 0 22741 GREGORY K HARMON CHAIRMAN 1.00 X X 0 0 0 KENNETH MORTENSON CHAIR. INV. 1.00 X X 0 0 0 BALDO SCASSELLATI SFORZOLINI DIRECTOR 1.00 X 0 0 0 JOHN BERDAHL DIRECTOR 1.00 X 0 0 0 REZA DIBADJ DIRECTOR 1.00 X 0 0 0 MURRAY FINGERET DIRECTOR 1.00 X 0 0 0 DAVID FELLOWS DIRECTOR 1.00 X 0 0 0 BARRY S FRIEDBERG DIRECTOR 1.00 X 0 0 0 JEFFREY M LIEBMANN DIRECTOR 1.00 X 0 0 0 KUMAR MAHADEVA DIRECTOR 1.00 X 0 0 0 JAI G PAREKH DIRECTOR 1.00 X 0 0 0 PATRICIA HILL DIRECTOR 1.00 X 0 0 0 JOE ROSEN DIRECTOR 1.00 X 0 0 0 LOUIS PASQUALE DIRECTOR 1.00 X 0 0 0 SHELDON M SIEGEL DIRECTOR 1.00 X 0 0 0 BARBARA CALABA DIRECTOR 1.00 X 0 0 0 CAROLE DARDEN-LLOYD DIRECTOR 1.00 X 0 0 0 ALON HARRIS DIRECTOR 1.00 X 0 0 0 ANNETTE GROLLMAN DIRECTOR 1.00 X 0 0 0 RAJEN SAVJANI DIRECTOR 1.00 X 0 0 0 BARBARA HEARST DIRECTOR 1.00 X 0 0 0 MITCH HILL DIRECTOR 1.00 X 0 0 0 686004 67855 3 false true false 269651 4775441 270323 5045092 390113 390113 1904823 1377036 527787 527787 527787 110128 269651 110128 5962992 917900 700700 700700 282107 282107 421778 295244 21091 105443 396084 312701 28503 54880 22223 16519 1347 4357 86390 64215 5239 16936 51160 38030 3102 10028 17250 17250 157443 157443 150250 14073 114274 21903 55303 41108 3354 10841 67586 50239 4098 13249 14175 14175 153126 153126 1048 778 64 206 7360 5471 446 1443 DIRECT MAIL 193408 157993 35415 COMMUNITY OUTREACH 161111 161111 POSTAGE AND SHIPPING 89788 67341 22447 FUNDRAISING FEES 23350 23350 6911 6911 3058551 2374931 338961 344659 1515978 659461 4925602 6537970 375000 1650000 91660 67001 102357 98384 3813 3973 9709581 10843751 148417 196150 815127 792026 17585178 20750332 163444 159088 412210 426404 40000 109068 787331 764230 1402985 1458790 X 9806400 10750550 6375793 8540992 16182193 19291542 17585178 20750332 2904441 204908 X false true X true false X 3616583 2557425 2676417 4042875 5045092 17938392 3616583 2557425 2676417 4042875 5045092 17938392 5760999 12177393 98435 325797 386991 355404 390113 1556740 60000 30000 90000 19585132 0.62180 0.64070 X PART II, LINE 10 90,000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 11186382 2500000 791528 540000 13937910 9630356 425912 1666026 535912 11186382 8757497 379932 1434859 941932 9630356 9907875 213554 -1150556 213376 8757497 8269730 928876 1587431 878162 9907875 0.41460 0.58540 false false 102357 98384 3973 3973 OPERATING LEASE LIABILITY 764230 764230 X 6010457 204908 204908 5805549 157443 157443 5962992 2901108 2901108 157443 157443 3058551 SCHEDULE D, PAGE 2, PART V, LINE 4 THE ORGANIZATION'S ENDOWMENT FUNDS ARE INTENDED TO BE USED FOR MEDICAL RESEARCH GRANTS. SCHEDULE D, PAGE 3, PART X THE FOUNDATION DOES NOT BELIEVE ITS FINANCIAL STATEMENTS INCLUDE ANY MATERIAL, UNCERTAIN TAX POSITIONS. TAX FILINGS FOR PERIODS ENDING DECEMBER 31, 2022 AND LATER ARE SUBJECT TO EXAMINATIONS BY APPLICABLE TAXING AUTHORITIES. true EUROPE GRANTS GRANTS 187500 EAST ASIA AND THE PACIFIC GRANTS GRANTS 74607 NORTH AMERICA CANADA GRANTS GRANTS 20000 282107 282107 GERMANY MEDICAL RESEARCH 112500 WIRE AUSTRALIA MEDICAL RESEARCH 74607 WIRE SWEDEN MEDICAL RESEARCH 75000 WIRE CANADA MEDICAL RESEARCH 20000 WIRE false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 2 RECIPIENTS MUST SUBMIT SEMI-ANNUAL REPORTS SHOWING PROGRESS AND EXPENDITURES. SCHEDULE F, PAGE 1, PART I, LINE 3 EUROPE 187,500 0 EAST ASIA AND THE PACIFIC 74,607 0 NORTH AMERICA CANADA 20,000 0 X X X true FAIRCOM NEW YORK 12 W 27TH ST FLOOR 13 NY NY 10001 DIRECT MAI false 459159 69000 390159 459159 69000 390159 ANNUAL GALA 379779 269651 110128 110128 379779 269651 110128 110128 110128 SCHEDULE G, PAGE 1, PART I, LINE 2B, COLUMN (V) FAIRCOM NEW YORK FEES true ICAHN SCHOOL OF MEDICINE 1 GUSTAVE L LEVY PL NEW YORK NY 10029 136171197 501(C) 73200 MEDICAL RESEARCH JOHN HOPKINS UNIVERSITY 400 N BROADWAY BALTIMORE MD 21287 520595110 501(C) 177500 MEDICAL RESEARCH COLUMBIA UNIVERSITY 116TH BROADWAY NEW YORK NY 10027 135598093 501(C) 75000 MEDICAL RESEARCH STANFORD UNIVERSITY 2452 WATSON COURT PALO ALTO CA 94303 941156365 501(C) 75000 MEDICAL RESEARCH UNIVERSITY OF CALIFORNIA IRVINE 324 ALDRICH HALL IRVINE CA 92697 952226406 501(C) 75000 MEDICAL RESEARCH UNIVERSITY OF MICHIGAN 100 WALL STREET ANN ARBOR MI 48105 386006309 501(C) 150000 MEDICAL RESEARCH HARVARD UNIVERSITY 243 CHARLES STREET BOSTON MA 02114 042103580 501(C) 75000 MEDICAL RESEARCH SCHEDULE I, PAGE 1, PART I, LINE 2 RECIPIENTS MUST SUBMIT SEMI-ANNUAL REPORTS SHOWING PROGRESS AND EXPENDITURES. X X X false false false false false false false false false ELENA STURMAN PRESIDENT & CEO 421776 22557 444333 ELENA CLY FOWKES DIR OF SPECIAL PROJ. 143934 22557 166491 X 1 270323 false false false FORM 990 - ORGANIZATION'S MISSION THE GLAUCOMA FOUNDATION, INC. IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA, THE LEADING CAUSE OF PREVENTABLE BLINDNESS. THE STRATEGY TO ACHIEVE THIS GOAL IS TWO-FOLD: RAISE PUBLIC AWARENESS CONCERNING THE NECESSITY OF ROUTINE EYE EXAMS, AND FUND CRITICAL RESEARCH TO FIND CURES FOR GLAUCOMA. FORM 990, PAGE 2, PART III, LINE 4A 1) MULTIPLE WEBINARS: WHAT DO COLD HANDS HAVE TO DO WITH GLAUCOMA? THE PROMISE OF OPTIC NERVE REGENERATION; THE BODY-EYE RELATIONSHIP HOW TO SAVE THE SIGHT OF PATIENTS WITH GLAUCOMA WHILE MINIMIZING ADVERSE REACTION FROM EYE DROPS; INSIGHTS INTO GLAUCOMA & WOMEN'S HEALTH: EXPLORING THE IMPACT OF MENOPAUSE AND VISUAL FUNCTION; GLAUCOMA AND LIFESTYLE. 2) THE OPTIC NERVE RESCUE AND RESTORATION THINK TANK "A PATIENT-CENTRIC APPROACH WHILE INCORPORATING THE LATEST SCIENCE" GLAUCOMA DATA INTEGRATION: OVERVIEW OF DATABASES AVAILABLE TO ADVANCE GLAUCOMA KNOWLEDGE; LESSONS LEARNED ABOUT GLAUCOMA FROM THE UK BIOBANK; POAG GENOMIC ARCHITECTURE; A 360-DEGREE BIOMEDICAL PROFILE OF HEALTH: LESSONS FROM CARDIOVASCULAR DISEASE. 3) DRUG RE-PURPOSING IN GLAUCOMA: INSULIN SIGNALING AND; METFORMIN AND GLAUCOMA; GLP-1R AGONISTS AND GLAUCOMA. 4) OVERVIEW OF GLAUCOMA NEUROPROTECTION AGENTS: WHY DO WE NOT HAVE A NEUROPROTECTION AGENT FOR GLAUCOMA? HOW CAN AI HELP FACILITATE RANDOMIZED CLINICAL TRIALS IN NEUROPROTECTION? 5) SEX HORMONES AND GLAUCOMA: THE ROLE OF SEX HORMONES IN THE PATHOGENESIS OF OPEN-ANGLE GLAUCOMA: EVIDENCE FROM EPIDEMIOLOGICAL STUDIES; ESTROGEN SIGNALING PATHWAYS IN GLAUCOMA; THE BIOMECHANICAL ARGUMENT THAT ESTROGEN PLAYS A ROLE IN GLAUCOMA; 6) NON-IOP FACTORS OF IMPORTANCE IN GLAUCOMA: DIET AND GLAUCOMA; HYPERTENSION, ANTIHYPERTENSIVE DRUGS AND GLAUCOMA; THE IMPACT OF GLAUCOMA ON ACTIVITIES OF DAILY LIVING. 7) WHAT CAN TGF DO TO HELP PATIENTS, RESEARCHERS, AND EYECARE PROVIDERS TACKLE GLAUCOMA?: WHAT IS THE GLAUCOMA FOUNDATION DOING NOW? WHAT DO PATIENTS WANT TO SEE IN GLAUCOMA RESEARCH? 8) START WITH THE YOUNG: INFO SESSION ON GLAUCOMA FOR MIDDLE AND HIGH SCHOOL STUDENTS; IN COORDINATION WITH THE STEM INSTITUTE AT THE CITY COLLEGE OF NEW YORK. 9) NEWSLETTERS: TGF PRODUCED SIX ELECTRONIC NEWSLETTERS THAT WERE DISTRIBUTED TO MORE THAN 16,000 HOUSEHOLDS. TGF'S QUARTERLY PRINTED NEWSLETTERS WERE AVAILABLE FOR CONSTITUENTS WHO DO NOT USE COMPUTERS OR WHO PREFER TO READ PAPER DOCUMENTS. NEWSLETTERS INCLUDE INTERVIEWS WITH DOCTORS, RESEARCHERS, AND PATIENTS. THEY COVER TOPICS SUCH AS ADVANCEMENTS IN DIAGNOSIS AND TREATMENT, PERSPECTIVES ON CARE, AND PERSONAL STORIES OF LIVING WITH THE DISEASE. FORM 990, PAGE 2, PART III, LINE 4B 1) GENETIC PREDISPOSITION AND OPHTHALMIC OUTCOMES; 2) OPTIC NERVE REGENERATION; 3) USING ARTIFICIAL INTELLIGENCE TO REVEAL BLOOD PRESSURE'S ROLE IN GLAUCOMA PROGRESSION; 4) EE-PURPOSING AN "OLD" DRUG FOR A NEW INDICATION: ELUCIDATING THE PERIPHERAL AND CENTRAL EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS TO TREAT GLAUCOMA; 5) SEARCH FOR FUNCTIONAL LOXL1 RISK ALLELES WITH BIT-STARR; 6) VASCULAR GENOTYPE-PHENOTYPE ASSOCIATION IN PRIMARY OPEN-ANGLE GLAUCOMA; 7) INVESTIGATING THE ROLE OF IMPAIRED MITOCHONDRIAL DYNAMICS IN EXFOLIATION GLAUCOMA; 8) UNCOVERING THE POTENTIAL OF PERICYTES AS THERAPEUTIC TARGETS FOR GLAUCOMA; 9) NICOTINAMIDE AND PYRUVATE FOR NEUROENHANCEMENT IN OPEN-ANGLE GLAUCOMA: A PHASE 2 RANDOMIZED CLINICAL TRIAL. FORM 990, PAGE 6, PART VI, LINE 11B THE CHIEF EXECUTIVE OFFICER AND THE ASSISTANT TREASURER REVIEW FORM 990 IN DETAIL AND THEN MAKE IT AVAILABLE TO THE GOVERNING BOARD PRIOR TO BEING FILED. FORM 990, PAGE 6, PART VI, LINE 12C THE ORGANIZATION HAS A BOARD APPROVED CONFLICT OF INTEREST POLICY. EACH BOARD MEMBER MUST FILL OUT AN ANNUAL DECLARATION STATING THEY HAD NO CONFLICTS OR IDENTIFYING THE NATURE OF THEIR INTERESTED PARTY TRANSACTIONS. FORM 990, PAGE 6, PART VI, LINE 15A EACH YEAR, THE COMPENSATION COMMITTEE REVIEWS COMPARABLE SALARIES BASED ON A RECOGNIZED STUDY AND REVIEWS THE PERFORMANCE OF THE PRESIDENT/CEO TO DETERMINE IF THE EXISTING SALARY FALLS WITHIN THESE RANGES. AFTER A DELIBERATION OF THIS MATTER, A NEW PROPOSED SALARY AND BENEFIT PACKAGE IS VOTED ON. THE MINUTES OF THE BOARD OF DIRECTORS REFLECT THE NATURE OF THIS PROCESS. FORM 990, PAGE 6, PART VI, LINE 15B EACH YEAR, THE COMPENSATION COMMITTEE REVIEWS COMPARABLE SALARIES BASED ON A RECOGNIZED STUDY AND REVIEWS THE PERFORMANCE OF THE PRESIDENT/CEO TO DETERMINE IF THE EXISTING SALARY FALLS WITHIN THESE RANGES. AFTER A DELIBERATION OF THIS MATTER, A NEW PROPOSED SALARY AND BENEFIT PACKAGE IS VOTED ON. THE MINUTES OF THE BOARD OF DIRECTORS REFLECT THE NATURE OF THIS PROCESS. FORM 990, PAGE 6, PART VI, LINE 17 MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION MAKES ITS PUBLIC DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO PUBLIC.